Progranulin, a new adipokine at the crossroads of metabolic syndrome, diabetes, dyslipidemia and hypertension.
CONCLUSION: Progranulin has both detrimental and beneficial effects. More clinical studies including prospective ones are needed to clarify the role of progranulin in obesity-associated pathologies such as diabetes, hyperlipidemia, hypertension and atherosclerosis.
PMID: 28120721 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Korolczuk A, Bełtowski J Tags: Curr Pharm Des Source Type: research
More News: Alcoholism | Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Hormones | Hypertension | Insulin | Liver | Liver Disease | Metabolic Syndrome | Neurology | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Study | Urology & Nephrology